Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,206.40
(
0.01%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
100.21
(
-0.98%
)
Bitcoin
78,075.01
(
-0.36%
)
News Focus
News Focus
Post# of 108195
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ignatiusrielly35

Send PM Follow Ignore
Followers 46
Posts 13651
Boards Moderated 0
Alias Born 11/18/2016

ignatiusrielly35

Re: DewDiligence post# 38738

Monday, 10/16/2017 7:25:06 PM

Monday, October 16, 2017 7:25:06 PM

Post# of 108195
Dew, why is there no shorter pathway to AA for Aim2Cerv? Also, when you say "AIM2CERV will almost certainly take longer to read out for DFS (the primary endpoint) than IMDZ's trial will take to read out for PFS" do you have any idea what the SPA called for? Cannot the FDA decide to grant AA at any time that it becomes likely that the benefit outweighs the risk, for serious diseases?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today